Merilym 3
Active substance
ATC code
Species
Dogs.
Indications
For active immunization of dogs from 12 weeks of age, to induce an anti-OspA response against Borrelia spp. (B. burgdorferi sensu stricto, B. garinii and B. afzelii).
Reduction of Borrelia transmission was only investigated under laboratory conditions, following a challenge with field ticks (collected from a region known to be affected by Borrelia). Under these conditions, it was shown that no Borrelia could be isolated from the skin of vaccinated dogs, while Borrelia were isolated from the skin of non vaccinated dogs.
Reduction of transmission of Borrelia from the tick to the host has not been quantified, and no correlation has been established between a specific level of antibodies and reduction of Borrelia transmission. The efficacy of the vaccine against an infection that leads to the development of clinical disease has not been studied.
Onset of immunity: 1 month after primary vaccination.
Duration of immunity: one year after primary vaccination.
Dose to be administered and administration route
Dose:
1 ml from 12 weeks of age.
Method of administration:
Subcutaneously.
Shake the vial well before use.
Primary vaccination:
Administer two doses separated by an interval of 3 weeks.
Revaccination:
Annual revaccination with a single dose is recommended to maintain immunity although this schedule has not been investigated.
Vaccination should be carried out prior to periods of increased tick activity, allowing sufficient time for the immune response to vaccination to develop fully (see section 4.2) prior to expected tick exposure.
Adverse reactions
Transitory swelling of up to 7 cm in diameter may be observed at the injection site for up to 5 days in rare cases. Anorexia or lethargy can be observed after treatment rarely.
Swellings of larger diameter (up to 15 cm) have been observed in very rare cases. A transient increase in body temperature (up to 1.5°C) may be induced very rarely. A hypersensitivity reaction may occur in very rare cases, which may require appropriate symptomatic treatment.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 08327/5035 |
| EAN | 3661103040910 |
